T cells engineered to express CD19-specific chimeric antigen receptors (CARs) have shown breakthrough clinical successes in patients with B-cell lymphoid malignancies. However, similar therapeutic efficacy of CAR T cells in solid tumors is yet to be achieved. In this study we systematically evaluated a series of CAR constructs targeting glypican-3 (GPC3), which is selectively expressed on several solid tumors. We compared GPC3-specific CARs that encoded CD3ζ (Gz) alone or with costimulatory domains derived from CD28 (G28z), 4-1BB (GBBz), or CD28 and 4-1BB (G28BBz). All GPC3-CARs rendered T cells highly cytotoxic to GPC3-positive hepatocellular carcinoma, hepatoblastoma, and malignant rhabdoid tumor cell lines in vitro. GBBz induced the preferential production of Th1 cytokines (interferon γ/granulocyte macrophage colony-stimulating factor) while G28z preferentially induced Th2 cytokines (interleukin-4/interleukin-10). Inclusion of 4-1BB in G28BBz could only partially ameliorate the Th2-polarizing effect of CD28. 4-1BB induced superior expansion of CAR T cells in vitro and in vivo. T cells expressing GPC3-CARs incorporating CD28, 4-1BB, or both induced sustained tumor regressions in two xenogeneic tumor models. Thus, GBBz CAR endows T cells with superior proliferative potential, potent antitumor activity, and a Th1-biased cytokine profile, justifying further clinical development of GBBz CAR for immunotherapy of GPC3-positive solid tumors.
Get full access to this article
View all access options for this article.
References
1.
SavoldoB, DottiG. Chimeric antigen receptors (CARs) from bench-to-bedside. Immunol Lett, 2013; 155:40–42.
2.
CurranKJ, PegramHJ, BrentjensRJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med, 2012; 14:405–415.
3.
GruppSA, KalosM, BarrettD, et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 2013; 368:1509–1518.
4.
KalosM, LevineBL, PorterDL, et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 2011; 3:95ra73.
5.
PorterDL, LevineBL, KalosM, BaggA, JuneCH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011; 365:725–733.
6.
MaudeSL, FreyN, ShawPA, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014; 371:1507–1517.
7.
KochenderferJN, DudleyME, KassimSH, et al.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol, 2015; 33:540–549.
8.
DavilaML, RiviereI, WangX, et al.Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014; 6:224ra225.
9.
LeeDW, KochenderferJN, Stetler-StevensonM, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 385:517–528.
10.
KohlerBA, ShermanRL, HowladerN, et al.Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst, 2015; 107:djv048.
11.
AhmedN, BrawleyVS, HegdeM, et al.Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol, 2015; 33:1688–1696.
12.
PuleMA, SavoldoB, MyersGD, et al.Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med, 2008; 14:1264–1270.
13.
LouisCU, SavoldoB, DottiG, et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 2011; 118:6050–6056.
14.
BeattyGL, HaasAR, MausMV, et al.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res, 2014; 2:112–120.
15.
AbkenH. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy, 2015; 7:535–544.
16.
GilhamDE, DebetsR, PuleM, HawkinsRE, AbkenH. CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med, 2012; 18:377–384.
17.
LamersCH, SleijferS, VultoAG, et al.Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol, 2006; 24:e20-e22.
18.
LamersCHJ, SleijferS, van SteenbergenS, et al.Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther, 2013; 21:904–912.
19.
GaoH, LiK, TuH, et al.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res, 2014; 20:6418–6428.
20.
WangXY, DegosFo, DuboisS, et al.Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol, 2006; 37:1435–1441.
21.
YamauchiN, WatanabeA, HishinumaM, et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol, 2005; 18:1591–1598.
22.
EnanET, El-HawaryAK, El-TantawyDAE-A, Abu-HashimMM, HelalNM. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions. Ann Diagn Pathol, 2013; 17:490–493.
23.
CostonWM, LoeraS, LauSK, et al.Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol, 2008; 32:433–444.
24.
BaumhoerD, TornilloL, StadlmannS, RoncalliM, DiamantisEK, TerraccianoLM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol, 2008; 129:899–906.
25.
ChanES, PawelBR, CoraoDA, et al.Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases. Pediatr Dev Pathol, 2013; 16:272–277.
26.
LevyM, TrivediA, ZhangJ, et al.Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol, 2012; 43:695–701.
27.
TretiakovaM, ZyngerDL, LuanC, et al.Glypican 3 overexpression in primary and metastatic Wilms tumors. Virchows Arch, 2015; 466:67–76.
28.
ZyngerDL, GuptaA, LuanC, ChouPM, YangGY, YangXJ. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol, 2008; 39:224–230.
29.
ZyngerDL, DimovND, LuanC, TehBT, YangXJ. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol, 2006; 30:1570–1575.
30.
YoritaK, TakahashiN, TakaiH, et al.Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int, 2011; 31:120–131.
31.
ShirakawaH, SuzukiH, ShimomuraM, et al.Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 2009; 100:1403–1407.
32.
NingS, BinC, NaH, et al.Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep, 2012; 39:351–357.
33.
YuMC, LeeYS, LinSE, et al.Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol, 2012; 19:S455–463.
34.
WangYL, ZhuZJ, TengDH, YaoZ, GaoW, ShenZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol, 2012; 18:2408–2414.
35.
FuSJ, QiCY, XiaoWK, LiSQ, PengBG, LiangLJ. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery, 2013; 154:536–544.
36.
CapurroM, MartinT, ShiW, FilmusJ. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci, 2014; 127:1565–1575.
37.
FilmusJ, CapurroM. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J, 2013; 280:2471–2476.
38.
ZhuAX, GoldPJ, El-KhoueiryAB, et al.First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2013; 19:920–928.
39.
IkedaM, OhkawaS, OkusakaT, et al.Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci, 2014; 105:455–462.
40.
LiK, PanX, BiY, et al.Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget, 2015.
41.
AbkenH, HombachA, HeuserC, KronfeldK, SeligerB. Tuning tumor-specific T-cell activation: a matter of costimulation?. Trends Immunol, 23:240–245.
42.
KunkeleA, JohnsonAJ, RolczynskiLS, et al.Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD. Cancer Immunol Res, 2015; 3:368–379.
43.
KrenciuteG, KrebsS, TorresD, et al.Characterization and functional analysis of scFv-based cars to redirect T cells to IL13Rα2-positive glioma. Mol Ther, 2015; 24:354–363.
44.
CarpenitoC, MiloneMC, HassanR, et al.Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA, 2009; 106:3360–3365.
45.
ZhongXS, MatsushitaM, PlotkinJ, RiviereI, SadelainM. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther, 2010; 18:413–420.
46.
RabinovichBA, YeY, EttoT, et al.Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA, 2008; 105:14342–14346.
47.
IshiguroT, SugimotoM, KinoshitaY, et al.Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res, 2008; 68:9832–9838.
48.
HeczeyA, LiuD, TianG, et al.Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood, 2014; 124:2824–2833.
49.
MiloneMC, FishJD, CarpenitoC, et al.Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther, 2009; 17:1453–1464.
50.
PuleMA, StraathofKC, DottiG, HeslopHE, RooneyCM, BrennerMK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther, 2005; 12:933–941.
51.
XuY, ZhangM, RamosCA, et al.Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood, 2014; 123:3750–3759.
52.
PhungY, GaoW, ManYG, NagataS, HoM. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs, 2012; 4:592–599.
53.
RooneyCM, RickinsonAB, MossDJ, LenoirGM, EpsteinMA. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. International journal of cancer. Int J Cancer, 1984; 34:339–348.
54.
HawkinsED, HommelM, TurnerML, BattyeFL, MarkhamJF, HodgkinPD. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat Protoc, 2007; 2:2057–2067.
55.
KakarlaS, ChowKK, MataM, et al.Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther, 2013; 21:1611–1620.
56.
FilmusJ, SelleckSB. Glypicans: proteoglycans with a surprise. J Clin Invest, 2001; 108:497–501.
57.
VeraJ, SavoldoB, VigourouxS, et al.T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 2006; 108:3890–3897.
58.
BrentjensRJ, SantosE, NikhaminY, et al.Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res, 2007; 13:5426–5435.
59.
SatoT, TeraiM, TamuraY, AlexeevV, MastrangeloM, SelvanS. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res, 2011; 51:170–182.
60.
ManninoMH, ZhuZ, XiaoH, BaiQ, WakefieldMR, FangY. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett, 2015; 367:103–107.
61.
WuAA, DrakeV, HuangH-S, ChiuS, ZhengL. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology, 2015; 4:e1016700.
62.
DennisKL, BlatnerNR, GounariF, KhazaieK. Current status of IL-10 and regulatory T-cells in cancer. Curr Opin Oncol, 2013; 25:637–645.
63.
DottiG, GottschalkS, SavoldoB, BrennerMK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev, 2014; 257:107–126.
64.
DottiG, SavoldoB, BrennerM. Fifteen years of gene therapy based on chimeric antigen receptors: “are we nearly there yet?”. Hum Gene Ther, 2009; 20:1229–1239.
65.
AliN, FlutterB, Sanchez RodriguezR, et al.Xenogeneic graft-versus-host-disease in NOD-IL-2Rγnull mice display a T-effector memory phenotype. PLoS One, 2012; 7:e44219.
66.
SavoldoB, RamosCA, LiuE, et al.CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest, 2011; 121:1822–1826.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
